Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gately

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLCSarah-Louise Ryan, Sam Beard, Martin P Barr, et al.
Scientific Reports|September 3, 2020
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancerSabina Luszczak, Benjamin S Simpson, Urszula Stopka-Farooqui, et al.
Scientific Reports|November 12, 2020
Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancerSabina Luszczak, Benjamin S Simpson, Urszula Stopka-Farooqui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLCSarah-Louise Ryan, Sam Beard, Martin P Barr, et al.
Scientific Reports|September 3, 2020
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancerSabina Luszczak, Benjamin S Simpson, Urszula Stopka-Farooqui, et al.
Scientific Reports|November 12, 2020
Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancerSabina Luszczak, Benjamin S Simpson, Urszula Stopka-Farooqui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Pageof 2